Could hepatitis C-Positive kidneys be safe for transplant?
NCT ID NCT03809533
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether kidneys from donors with hepatitis C can be safely transplanted into people without the virus. Recipients will take the antiviral drug Epclusa for 12 weeks to prevent or treat infection. The goal is to see if this approach is safe and effective, potentially increasing the number of available kidneys for transplant.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sofosbuvir/Velpatasvir (Epclusa)
- What this could lead to
- If successful, this could expand the donor pool for kidney transplants by safely using organs from hepatitis C-positive donors.
- What could go wrong
- This is a small, early-phase trial with only 30 participants, so results may not apply broadly. There is a risk of HCV transmission or side effects from the antiviral drug.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
UPMC
Pittsburgh, Pennsylvania, 15213, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug work safely in patients with kidney failure?
- A Finger-Prick could change the fight against hepatitis c
- A simple finger prick could transform hepatitis c care
- Can coaching clinics curb HIV? a new strategy puts it to the test
- What does life feel like for children with a rare birth defect? a new study asks
- AI therapy coach aims to ease distress in seriously ill seniors